HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Analytical, ultrastructural, autoradiographic and biochemical studies on [3H]dicarboxylic acid added to cultures of melanoma cells.

Abstract
Lentigo maligna and malignant melanoma can be treated by dicarboxylic acids (C9 and C12), which are competitive inhibitors of tyrosinase. We therefore studied the intracellular location and possible sites of action of dodecanedioic acid (C12) in murine melanoma cells, using EM autoradiography and biochemical analysis of lipid extracts by HPLC. Significant levels of radioactivity were found in the mitochondria and in the nuclei but not in association with membranes of rough endoplasmic reticulum, Golgi-associated endoplasmic reticulum, or Golgi apparatus, and not in coated vesicles or melanosomes. Biochemical analysis revealed that the diacid underwent beta-oxidation, which occurs only in mitochondria. The results suggest that the toxicity of dicarboxylic acids in melanoma cells is not related to anti-tyrosinase activity but may be due to interference with oxidoreductase enzymes in the mitochondria and possibly to inhibition of DNA synthesis in the nucleus.
AuthorsB J Ward, A S Breathnach, E J Robins, Y Bhasin, L Ethridge, S Passi, M Nazzaro-Porro
JournalThe British journal of dermatology (Br J Dermatol) Vol. 111 Issue 1 Pg. 29-36 (Jul 1984) ISSN: 0007-0963 [Print] ENGLAND
PMID6743538 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dicarboxylic Acids
  • Tritium
  • dodecanedioic acid
Topics
  • Animals
  • Autoradiography
  • Cells, Cultured
  • Dicarboxylic Acids (metabolism)
  • Humans
  • Lipid Metabolism
  • Melanoma (metabolism, ultrastructure)
  • Mice
  • Microscopy, Electron
  • Subcellular Fractions (metabolism, ultrastructure)
  • Time Factors
  • Tritium

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD